First Patients Dosed in jCyte’s Phase II JC02-88 Trial for Retinitis Pigmentosa
jCyte turns up the dose, chasing broader answers for a disease with few options. A higher dose, a broader target…
ViGeneron Rebrands as VeonGen Therapeutics, Accelerates Clinical Pipeline in IRDs
VeonGen Therapeutics debuts with FDA recognition and bold plans for inherited eye diseases. ViGeneron (Munich, Germany) announced its rebranding as…
popular posts
latest posts